Chronic Stress and Inflammation Linked to Structural Heart Damage

Chronic stress and persistent systemic inflammation may be quietly reshaping the human heart, potentially leading to long-term structural damage years before clinical symptoms emerge. A new study, published in the European Journal of Preventive Cardiology, analyzed data from nearly 480,000 adults in the UK to establish a link between lifestyle-driven inflammation and cardiovascular risk.

Researchers led by Imperial College London utilized UK Biobank data, incorporating heart imaging, genetic information, and blood markers. They specifically tracked glycoprotein acetyls (GlycA), a biomarker for systemic inflammation. The findings indicate that individuals in the top 20 percent for inflammation levels face a 43 percent higher risk of heart attack and stroke compared to those in the lowest 20 percent, even in the absence of pre-existing heart disease.

GlycA is a composite nuclear magnetic resonance biomarker reflecting the N-glycosylation of multiple acute-phase glycoproteins and shows greater long-term biological stability over years than single-protein acute-phase markers like hsCRP. Additionally, researchers demonstrated that interleukin-1 receptor antagonist and related cytokines statistically mediate a portion of the relationship between systemic inflammation and adverse cardiac structural remodeling.

The study identified that elevated inflammation is associated with measurable physical remodeling of the heart. Participants with higher GlycA levels exhibited thickened heart walls, smaller heart chambers, and impaired heart filling. These structural alterations can progress silently over years, eventually increasing the risk of heart failure. The researchers identified circulating cytokines and growth factors, specifically within the interleukin-1 and TNF families, as potential mediators in this process.

The research highlights that chronic inflammation is not merely a clinical marker but is deeply tied to external stressors. Higher inflammation levels were strongly correlated with socioeconomic disadvantage, psychological distress, and established risk factors such as smoking and excess body fat. According to the study authors, this suggests that chronic inflammation serves as a biological pathway through which poverty and mental health challenges manifest as physical cardiovascular damage.

While the findings underscore the impact of environmental and social factors on heart health, the researchers emphasized that heart disease is not an inevitable outcome. Professor Declan O'Regan, the study's lead author, noted that reducing risk factors like smoking and obesity can mitigate inflammatory damage. Furthermore, the identification of specific inflammatory proteins already targeted by existing clinical-trial drugs raises the possibility that anti-inflammatory therapies could eventually be used to prevent cardiovascular disease before structural damage becomes irreversible. The team suggests that integrating inflammation blood tests with genetic risk scores could help clinicians identify high-risk individuals for earlier intervention.

Ziltivekimab is being evaluated in Phase 3 cardiovascular outcome trials such as the ZEUS trial and HERMES trial for the prevention of atherosclerotic disease and heart failure. Furthermore, the inhibition of the interleukin-1 pathway using canakinumab and anakinra, alongside low-dose colchicine, has provided clinical evidence that reducing vascular inflammation lowers cardiovascular events.